GET DAILY SIGNALSCharles River Laboratories (CRL) Q3 2026 Earnings Outlook: Building on the Recent Turnaround
Key Takeaways
- Charles River Laboratories is expected to report its third-quarter 2026 results in early November, following a second quarter that delivered the company's first organic revenue growth since 2023.
- Management has guided for organic revenue to turn positive again in the third quarter, led by accelerating demand in its Discovery and Safety Assessment (DSA) segment.
- The DSA net book-to-bill ratio reached roughly 1.2x in the second quarter — the third consecutive quarter above 1x and its highest level in nearly four years.
- Full-year 2026 guidance was raised in August to organic revenue growth of 0.0% to 1.0% and non-GAAP earnings per share (EPS) of $11.15 to $11.45.
- Reported (GAAP) results remain pressured by divestiture-related losses, with full-year GAAP EPS guidance of $3.05 to $3.35.
- Investors are watching biotech funding trends, non-human primate (NHP) supply costs, and the pace of portfolio divestitures as key swing factors.
Putting the Earnings in Context
Charles River Laboratories, a leading provider of research models and preclinical drug development services, is working through a multi-year reset after biopharmaceutical clients pulled back on early-stage research spending. Its second-quarter 2026 report marked a potential inflection, with total organic revenue rising 0.1% — the first increase since the third quarter of 2023. The upcoming third-quarter report will test whether that momentum is durable, particularly in the DSA segment, which accounts for the majority of revenue. With the company having completed several divestitures to sharpen its portfolio, investors are looking for evidence that the core regulated-testing business can sustain growth and rebuild earnings power. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What to Expect from the Quarter
Heading into the third quarter of 2026, the focus is on whether Charles River can extend its return to organic growth. Management said in August that it expects "incremental organic revenue growth starting in the third quarter," driven by improving demand trends in the Discovery and Safety Assessment (DSA) segment. For the full year, the company raised its organic revenue outlook to growth of 0.0% to 1.0% and its non-GAAP EPS guidance to $11.15 to $11.45, up $0.25 at the midpoint. That implies a meaningful step-up in back-half earnings after a second-quarter non-GAAP EPS of $3.02.
Key metrics investors will watch include the DSA net book-to-bill ratio — which reached roughly 1.2x in the second quarter — and the segment's backlog, reported at about $1.97 billion. Bookings above 1x signal that new orders are outpacing revenue, a leading indicator of future growth. Biotech funding conditions, NHP supply costs, and margin trends across the DSA, Research Models and Services (RMS), and Manufacturing segments will also be closely scrutinized.
Market Sentiment Around the Stock
Sentiment around CRL has improved alongside signs of a biotech funding recovery, but caution persists. The company's August report beat expectations on non-GAAP EPS and organic growth, yet a GAAP loss and lower GAAP EPS guidance underscored the lingering drag from divestitures. Into the third-quarter report, investors are weighing the improving DSA demand outlook against execution risk tied to the portfolio reshape and constrained academic and government research spending. A clear beat on organic growth and DSA bookings could reinforce the turnaround narrative, while any reversal in demand trends would likely pressure the shares.
Key Factors to Watch Going Forward
Beyond the third-quarter print, the trajectory of DSA demand will be the central story. The company has pointed to three consecutive quarters with a book-to-bill ratio above 1x, and a sustained reading at or above that level would support continued organic growth into 2027. Watch for commentary on small- and mid-sized biotech funding, which management has described as resilient and broad-based, as well as any signs of renewed spending from large global biopharmaceutical clients.
Margin recovery is another important theme. Management has targeted at least 500 basis points of sequential operating-margin improvement in the second half of the year, aided by divestitures and lower NHP-related costs. Investors should monitor whether the Manufacturing segment's elevated profitability holds and whether RMS can stabilize amid softer North American research-model volumes.
Finally, capital deployment and the remainder of the portfolio reshape matter. With divestitures of the CDMO (contract development and manufacturing organization) and Cell Solutions businesses complete, attention turns to reinvesting proceeds, the $1 billion buyback authorization, and any targeted M&A (mergers and acquisitions) in bioanalysis and in vitro services. These factors will shape both near-term earnings quality and longer-term growth. From what I see, the AI Daily Buy/Sell Signals tool has been helpful for spotting similar setups in the sector.
Using AI Tools in My Research Process
In my own analysis, I often turn to Tickeron’s AI Screener to quickly filter through industry peers and identify stocks showing similar technical patterns or fundamental improvements. It allows me to scan for earnings-related setups and compare volatility or performance metrics across the sector without spending hours on manual work. This kind of tool has become a regular part of how I prepare for reports like the one coming from CRL, helping surface context that supports the broader narrative around demand trends and bookings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CRL in +4.81% Uptrend, advancing for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CRL advanced for three days, in 199 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Aroon Indicator entered an Uptrend today. In 150 of 228 cases where CRL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 66%.
Bearish Trend Analysis
The 10-day RSI Indicator for CRL moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 22 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 67 cases where CRL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRL as a result. In 64 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for CRL turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 35 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
CRL broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 1 (best 1 - 100 worst), indicating outstanding price growth. CRL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.485) is normal, around the industry mean (66.911). P/E Ratio (-67.836) is within average values for comparable stocks, (2.514). Projected Growth (PEG Ratio) (0.122) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.340) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of laboratory testing and research services on a contract basis
Industry MedicalSpecialties
Advertisement